$IMUC
EOM Pharmaceutical Holdings, Inc.

2013 Q2 Form 10-Q Financial Statement

#000095012313003511 Filed on May 10, 2013

View on sec.gov

Income Statement

Concept 2013 Q2 2013 Q1 2012 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $970.0K $930.0K $1.050M
YoY Change 3.19% -11.43% 31.25%
% of Gross Profit
Research & Development $1.210M $1.415M $1.999M
YoY Change -44.74% -29.19% 117.23%
% of Gross Profit
Depreciation & Amortization $10.84K $10.84K $11.44K
YoY Change -5.26% -5.26%
% of Gross Profit
Operating Expenses $2.180M $1.415M $1.999M
YoY Change -0.44% -29.19% 16.87%
Operating Profit -$2.182M -$2.349M -$3.049M
YoY Change -30.3% -22.98%
Interest Expense $2.030M -$2.630M -$4.840M
YoY Change -161.14% -45.66% 360.95%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$150.3K -$4.974M -$7.889M
YoY Change -97.67% -36.96% 185.85%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$150.3K -$4.974M -$7.889M
YoY Change -97.67% -36.96% 185.85%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 -$0.10 -$0.21
Diluted Earnings Per Share $0.00 -$0.10 -$0.21
COMMON SHARES
Basic Shares Outstanding 52.73M
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q2 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $25.45M $24.10M $13.56M
YoY Change 124.43% 77.73% 20.53%
Cash & Equivalents $25.45M $24.10M $13.56M
Short-Term Investments
Other Short-Term Assets $400.0K $818.0K $740.0K
YoY Change -35.48% 10.55% 1133.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $25.85M $24.92M $14.30M
YoY Change 116.14% 74.28% 26.44%
LONG-TERM ASSETS
Property, Plant & Equipment $90.00K $61.63K $110.0K
YoY Change -10.0% -43.97% 120.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $241.6K $90.00K $10.00K
YoY Change 2315.75% 800.0% 0.0%
Total Long-Term Assets $330.0K $148.4K $120.0K
YoY Change 230.0% 23.64% 100.0%
TOTAL ASSETS
Total Short-Term Assets $25.85M $24.92M $14.30M
Total Long-Term Assets $330.0K $148.4K $120.0K
Total Assets $26.18M $25.07M $14.42M
YoY Change 117.08% 73.86% 26.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $330.0K $705.9K $700.0K
YoY Change -42.11% 0.84% 1300.0%
Accrued Expenses $490.0K $362.3K $740.0K
YoY Change 8.89% -51.04% 105.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $820.0K $1.158M $1.440M
YoY Change -19.61% -19.59% 251.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.310M $5.480M $6.420M
YoY Change -73.45% -14.64% 5.07%
Total Long-Term Liabilities $2.310M $5.480M $6.420M
YoY Change -73.45% -14.64% 5.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $820.0K $1.158M $1.440M
Total Long-Term Liabilities $2.310M $5.480M $6.420M
Total Liabilities $3.130M $6.640M $7.870M
YoY Change -67.8% -15.63% 20.71%
SHAREHOLDERS EQUITY
Retained Earnings -$48.14M
YoY Change
Common Stock $5.167K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.05M $18.43M $6.550M
YoY Change
Total Liabilities & Shareholders Equity $26.18M $25.07M $14.42M
YoY Change 117.08% 73.86% 26.82%

Cashflow Statement

Concept 2013 Q2 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$150.3K -$4.974M -$7.889M
YoY Change -97.67% -36.96% 185.85%
Depreciation, Depletion And Amortization $10.84K $10.84K $11.44K
YoY Change -5.26% -5.26%
Cash From Operating Activities -$1.910M -$2.207M -$3.579M
YoY Change -42.3% -38.32% 132.37%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $0.00 $5.668K
YoY Change -100.0% -114.17%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities -$30.00K $0.00 -$5.668K
YoY Change -100.0% -85.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.300M 94.86K 10.49M
YoY Change 202.75% -99.1% 39.64%
NET CHANGE
Cash From Operating Activities -1.910M -2.207M -3.579M
Cash From Investing Activities -30.00K 0.000 -5.668K
Cash From Financing Activities 3.300M 94.86K 10.49M
Net Change In Cash 1.360M -2.112M 6.903M
YoY Change -161.26% -130.6% 16.4%
FREE CASH FLOW
Cash From Operating Activities -$1.910M -$2.207M -$3.579M
Capital Expenditures -$30.00K $0.00 $5.668K
Free Cash Flow -$1.880M -$2.207M -$3.584M
YoY Change -43.2% -38.42% 138.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1098307
CY2012Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1998536
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
164128
CY2012Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
245107
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
769267
CY2013Q1 us-gaap Costs And Expenses
CostsAndExpenses
2348656
CY2012Q1 us-gaap Costs And Expenses
CostsAndExpenses
3049441
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2348656
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3049441
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
6548
CY2012Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1034
CY2004Q4 us-gaap Stockholders Equity
StockholdersEquity
-11494
CY2013Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000822411
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8880140
us-gaap Costs And Expenses
CostsAndExpenses
42009528
us-gaap Operating Income Loss
OperatingIncomeLoss
-41709528
us-gaap Investment Income Interest
InvestmentIncomeInterest
354292
CY2013Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
CY2012Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
368524
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
397294
CY2013Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-2631683
CY2012Q1 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-4472504
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4973791
CY2012Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7889435
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-46050121
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2012Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Net Income Loss
NetIncomeLoss
-46050121
CY2013Q1 us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
0
CY2012Q1 us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
0
us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
2092500
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4973791
CY2012Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7889435
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-48142621
CY2013Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q1 dei Entity Registrant Name
EntityRegistrantName
ImmunoCellular Therapeutics, Ltd.
CY2013Q1 dei Document Type
DocumentType
10-Q
CY2013Q1 dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
CY2013Q1 us-gaap Assets Current
AssetsCurrent
24922300
CY2012Q1 us-gaap Revenues
Revenues
0
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
5150
CY2013Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
86735
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
309345
CY2012Q4 us-gaap Assets Current
AssetsCurrent
26931176
CY2012Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2852880
CY2012Q4 us-gaap Assets
Assets
27019201
CY2013Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
89698
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1157888
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
362292
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
56111
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26216668
CY2013Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
5484562
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61629
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48142621
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52728483
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
23068014
CY2013Q1 us-gaap Revenues
Revenues
0
CY2013Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
705898
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43168830
CY2013Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51500996
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
18428214
CY2013Q1 us-gaap Other Assets Current
OtherAssetsCurrent
818042
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
714508
CY2012Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
11736
CY2013Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51673145
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51500996
CY2013Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
5167
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
66565668
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
66231694
us-gaap Revenues
Revenues
300000
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25070664
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27019201
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
99000000
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
99000000
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
51673145
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24104258
CY2013Q1 us-gaap Assets
Assets
25070664
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
732851
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19675374
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1415261
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
76289
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13454014
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-4297591
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-4973791
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-7889435
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17526930
CY2012Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36984459
CY2012Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
805798
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51547632
CY2005Q4 us-gaap Stockholders Equity
StockholdersEquity
20262
CY2008 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
513357
CY2013Q1 imuc Earning Before Dividend Adjustment Per Share Basic And Diluted
EarningBeforeDividendAdjustmentPerShareBasicAndDiluted
-0.010
CY2012Q1 imuc Earning Before Dividend Adjustment Per Share Basic And Diluted
EarningBeforeDividendAdjustmentPerShareBasicAndDiluted
-0.21
imuc Earning Before Dividend Adjustment Per Share Basic And Diluted
EarningBeforeDividendAdjustmentPerShareBasicAndDiluted
-2.75
CY2004Q1 us-gaap Stockholders Equity
StockholdersEquity
97
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
150
us-gaap Net Income Loss
NetIncomeLoss
-11741
CY2005 imuc Common Stock Issued For Research And Development
CommonStockIssuedForResearchAndDevelopment
152760
CY2005 us-gaap Net Income Loss
NetIncomeLoss
-246004
CY2006 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
36546
CY2006 imuc Common Stock Issued For Cash During Private Placements Net Of Redemptions
CommonStockIssuedForCashDuringPrivatePlacementsNetOfRedemptions
549400
CY2006 imuc Common Stock Issued For Research And Development
CommonStockIssuedForResearchAndDevelopment
694000
CY2006 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0
CY2006 imuc Share Cancelled In Connection With Sale Of Affiliate
ShareCancelledInConnectionWithSaleOfAffiliate
-65000
CY2006 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3522
CY2006 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4103645
CY2006 us-gaap Net Income Loss
NetIncomeLoss
-5152713
CY2006Q4 us-gaap Stockholders Equity
StockholdersEquity
189662
CY2007 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4892486
CY2007 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2007 imuc Reclassification Of Warrant Derivative Liability
ReclassificationOfWarrantDerivativeLiability
2233600
CY2007 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1296714
CY2007 us-gaap Net Income Loss
NetIncomeLoss
-3614753
CY2007Q4 us-gaap Stockholders Equity
StockholdersEquity
4997709
CY2008 us-gaap Net Income Loss
NetIncomeLoss
-3059730
CY2008Q4 us-gaap Stockholders Equity
StockholdersEquity
2940336
CY2009 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
462748
CY2009 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11814
CY2009 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
308302
CY2009 us-gaap Net Income Loss
NetIncomeLoss
-2626205
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
1096995
CY2010 imuc Common Stock And Warrants Issued For Cash Net Of Offering Costs
CommonStockAndWarrantsIssuedForCashNetOfOfferingCosts
3248738
CY2010 imuc Preferred Stock And Warrants Issued For Cash Net Of Offering Costs
PreferredStockAndWarrantsIssuedForCashNetOfOfferingCosts
0
CY2010 imuc Exercise Of Warrants In Exchange For Promissory Note
ExerciseOfWarrantsInExchangeForPromissoryNote
0
CY2010 imuc Redemption Of Preferred Stock For Repayment Of Promissory Note
RedemptionOfPreferredStockForRepaymentOfPromissoryNote
3307500
CY2010 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
26500
CY2010 imuc Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
0
CY2010 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
745697
CY2010 imuc Interest On Promissory Note
InterestOnPromissoryNote
-1614
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-6150142
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
2335830
CY2011 imuc Common Stock And Warrants Issued For Cash Net Of Offering Costs
CommonStockAndWarrantsIssuedForCashNetOfOfferingCosts
4983339
CY2011 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
388379
CY2011 imuc Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
0
CY2011 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1190133
CY2011 imuc Interest On Promissory Note
InterestOnPromissoryNote
-352
CY2011 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
54634
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-5719903
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
3232060
CY2012 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3201920
CY2012 imuc Reclassification Of Warrant Derivative Liability
ReclassificationOfWarrantDerivativeLiability
1981743
CY2012 imuc Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
0
CY2012 imuc Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
0
CY2012 imuc Restricted Stock Value Shares Issued Vested
RestrictedStockValueSharesIssuedVested
0
CY2012 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
496007
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20500
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-14495139
CY2013Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
10732
us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
53018
CY2013Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
103533
CY2013Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
84131
CY2013Q1 imuc Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
0
CY2013Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
164128
CY2013Q1 imuc Initial Capitalization Per Share
InitialCapitalizationPerShare
0.00002
CY2013Q1 imuc Common Stock Issued For Cash Per Share
CommonStockIssuedForCashPerShare
0.00078
CY2006 imuc Common Stock Issued For Services Per Share
CommonStockIssuedForServicesPerShare
0.50
CY2005 imuc Common Stock Issued For Research And Development Per Share
CommonStockIssuedForResearchAndDevelopmentPerShare
0.99
CY2006 imuc Common Stock Issued For Research And Development Per Share
CommonStockIssuedForResearchAndDevelopmentPerShare
1.00
CY2006 imuc Common Stock Issued For Cash In Private Placements Per Share
CommonStockIssuedForCashInPrivatePlacementsPerShare
1.00
CY2007 imuc Common Stock Issued For Cash In Private Placements Per Share
CommonStockIssuedForCashInPrivatePlacementsPerShare
1.50
CY2010 imuc Common Stock And Warrants Issued For Cash Per Share
CommonStockAndWarrantsIssuedForCashPerShare
1.00
CY2011 imuc Common Stock And Warrants Issued For Cash Per Share
CommonStockAndWarrantsIssuedForCashPerShare
1.55
CY2010 imuc Preferred Stock And Warrants Issued For Cash Per Share
PreferredStockAndWarrantsIssuedForCashPerShare
10000
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
10842
CY2012Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11444
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
86127
CY2013Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-3817
CY2012Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-3817
CY2013Q1 imuc Interest Accrued On Promissory Note
InterestAccruedOnPromissoryNote
0
CY2012Q1 imuc Interest Accrued On Promissory Note
InterestAccruedOnPromissoryNote
0
imuc Interest Accrued On Promissory Note
InterestAccruedOnPromissoryNote
0
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
164128
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
245107
us-gaap Share Based Compensation
ShareBasedCompensation
8817984
CY2013Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
CY2012Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
98703
CY2013Q1 imuc Common Stock Issued For Research And Development
CommonStockIssuedForResearchAndDevelopment
0
CY2012Q1 imuc Common Stock Issued For Research And Development
CommonStockIssuedForResearchAndDevelopment
0
imuc Common Stock Issued For Research And Development
CommonStockIssuedForResearchAndDevelopment
1335760
CY2012Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
651229
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
895940
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-26953
CY2012Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-430720
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
705548
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
86534
CY2012Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
295239
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
451990
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2207273
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3578566
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30751247
CY2013Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2012Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5668
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
155692
CY2013Q1 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0
CY2012Q1 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
-25000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5668
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-180692
CY2013Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
84131
CY2012Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
534844
CY2012Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1115605
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3675398
CY2013Q1 us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
0
CY2012Q1 us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
0
CY2013Q1 imuc Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering
ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering
0
CY2012Q1 imuc Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering
ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering
9371370
imuc Proceeds From Issuance Of Common Stock And Warrants From Underwritten Public Offering
ProceedsFromIssuanceOfCommonStockAndWarrantsFromUnderwrittenPublicOffering
46993779
CY2013Q1 imuc Proceeds From Issuance Of Preferred Stock And Warrants Net Of Offering Costs
ProceedsFromIssuanceOfPreferredStockAndWarrantsNetOfOfferingCosts
0
CY2012Q1 imuc Proceeds From Issuance Of Preferred Stock And Warrants Net Of Offering Costs
ProceedsFromIssuanceOfPreferredStockAndWarrantsNetOfOfferingCosts
0
imuc Proceeds From Issuance Of Preferred Stock And Warrants Net Of Offering Costs
ProceedsFromIssuanceOfPreferredStockAndWarrantsNetOfOfferingCosts
3779158
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
94863
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10486975
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55036197
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2112410
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6902741
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
24104258
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6653168
CY2004Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13555909
CY2013Q1 us-gaap Interest Paid
InterestPaid
CY2012Q1 us-gaap Interest Paid
InterestPaid
us-gaap Interest Paid
InterestPaid
CY2013Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
CY2012Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
us-gaap Income Taxes Paid
IncomeTaxesPaid
imuc Exercise Of Warrants In Exchange For Promissory Note
ExerciseOfWarrantsInExchangeForPromissoryNote
3350000
imuc Redemption Of Preferred Stock For Repayment Of Promissory Note
RedemptionOfPreferredStockForRepaymentOfPromissoryNote
3350000
CY2013Q1 imuc Warrant Liability Converted To Additional Paid In Capital Upon Exercise
WarrantLiabilityConvertedToAdditionalPaidInCapitalUponExercise
0
CY2012Q1 imuc Warrant Liability Converted To Additional Paid In Capital Upon Exercise
WarrantLiabilityConvertedToAdditionalPaidInCapitalUponExercise
575197
imuc Warrant Liability Converted To Additional Paid In Capital Upon Exercise
WarrantLiabilityConvertedToAdditionalPaidInCapitalUponExercise
1981745
CY2013Q1 us-gaap Escrow Deposit Disbursements Related To Property Acquisition
EscrowDepositDisbursementsRelatedToPropertyAcquisition
0
CY2012Q1 us-gaap Escrow Deposit Disbursements Related To Property Acquisition
EscrowDepositDisbursementsRelatedToPropertyAcquisition
35882
us-gaap Escrow Deposit Disbursements Related To Property Acquisition
EscrowDepositDisbursementsRelatedToPropertyAcquisition
35882
imuc Non Cash Deferred Offering Costs
NonCashDeferredOfferingCosts
182599
CY2013Q1 imuc Common Stock Issued For License Rights
CommonStockIssuedForLicenseRights
75000
imuc Common Stock Issued For License Rights
CommonStockIssuedForLicenseRights
75000
CY2012Q4 imuc Stock Issued During Period Shares Private Placement
StockIssuedDuringPeriodSharesPrivatePlacement
10000000
CY2013Q1 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
generally three to five years
CY2013Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2013Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin:0pt; text-indent:24.5pt"><font style="font-family:'Times New Roman'; font-size:10pt; font-style:italic">Use of Estimates</font><font style="font-family:'Times New Roman'; font-size:10pt"> &#8211; The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these financial statements. </font></p> </div>
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0074
CY2012Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0080
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2012Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y6M
CY2012Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y9M18D
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.906
CY2012Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.754
CY2013Q1 imuc Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate
0.00
CY2012Q1 imuc Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeituresRate
0.00
CY2013Q1 imuc Working Capital
WorkingCapital
23764412
CY2012Q4 imuc Working Capital
WorkingCapital
25832869
CY2013Q1 imuc Maturity Period Of Highly Liquid Instruments To Be Considered As Cash Equivalents Maximum
MaturityPeriodOfHighlyLiquidInstrumentsToBeConsideredAsCashEquivalentsMaximum
P90D
CY2013Q1 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
23403470
CY2012Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
23646922
CY2013Q1 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
21100000
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24172596
CY2012Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15895165
CY2013Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
141001
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
151573
CY2013Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
-79372
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
-75284
CY2013Q1 us-gaap Depreciation
Depreciation
10842
CY2012Q1 us-gaap Depreciation
Depreciation
11444
us-gaap Depreciation
Depreciation
86127
CY2006Q4 imuc Stock Issued During Period Shares Issued For Upfront Licensing Fee
StockIssuedDuringPeriodSharesIssuedForUpfrontLicensingFee
694000
CY2006Q4 imuc Payment For Upfront Licensing Fee
PaymentForUpfrontLicensingFee
62000
CY2008Q4 imuc Funding From Equity For Milestone Minimum
FundingFromEquityForMilestoneMinimum
5000000
CY2009Q4 imuc Payment To Related Party For Clinical Trial
PaymentToRelatedPartyForClinicalTrial
166660
CY2008Q2 imuc Stock Issued During Period Shares Issued For Additional Licensing Fee
StockIssuedDuringPeriodSharesIssuedForAdditionalLicensingFee
100000
CY2010Q4 imuc Amount Of Funding From Equity Minimum After Amendment
AmountOfFundingFromEquityMinimumAfterAmendment
2500000
CY2011Q3 imuc Amount Of Funding From Equity Minimum After Amendment
AmountOfFundingFromEquityMinimumAfterAmendment
5000000
CY2013Q1 us-gaap Related Party Transaction Other Revenues From Transactions With Related Party
RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
330000
CY2013Q1 imuc Extended Term Of Agreement
ExtendedTermOfAgreement
2014-03-31
CY2013Q1 imuc Period Within Effective Date Of License Agreement
PeriodWithinEffectiveDateOfLicenseAgreement
P30D
CY2013Q1 imuc Nonrefundable And Noncreditable License And Maintenance Fee
NonrefundableAndNoncreditableLicenseAndMaintenanceFee
P12M
CY2011Q4 imuc Additional Purchase Of Stock Option
AdditionalPurchaseOfStockOption
10000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
15230310
CY2011Q2 imuc Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Under Condition Three
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodUnderConditionThree
20000
CY2012 imuc Number Of Patients
NumberOfPatients
75
CY2012Q1 imuc Additional Purchase Of Stock Option
AdditionalPurchaseOfStockOption
10000
CY2011Q2 imuc Terms Of Installment For Options To Vest
TermsOfInstallmentForOptionsToVest
P3Y
CY2011Q2 imuc Share Based Compensation Arrangement By Share Based Payment Award Options First Vesting Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFirstVestingDate
2012-01-31
CY2011Q2 imuc Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Under Condition One
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodUnderConditionOne
20000
CY2011Q2 imuc Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Under Condition Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodUnderConditionTwo
20000
CY2013Q1 imuc Maximum Exercisable Period Of Options If Percentage Of Common Stock Voting Rights Held Is More Than Ten Percent
MaximumExercisablePeriodOfOptionsIfPercentageOfCommonStockVotingRightsHeldIsMoreThanTenPercent
P5Y
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2052032
CY2013Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1823276
CY2013Q1 imuc Employee Service Share Based Compensation Nonvested Awards Compensation Cost Not Yet Recognized Period For Recognition Maximum
EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedPeriodForRecognitionMaximum
22 Months
CY2013Q1 imuc Common Stock Shares Purchased Private Placement Warrant
CommonStockSharesPurchasedPrivatePlacementWarrant
2823670
CY2012Q4 imuc Common Stock Of Public Offering
CommonStockOfPublicOffering
2823670
CY2012Q4 imuc Adjusted Exercise Price Of Warrants
AdjustedExercisePriceOfWarrants
1.87
CY2013Q1 imuc Common Stock Warrants Exercise Price Private Placement
CommonStockWarrantsExercisePricePrivatePlacement
2.74
CY2012 imuc Common Stock Warrants Exercise Price Private Placement
CommonStockWarrantsExercisePricePrivatePlacement
1.92
CY2013Q1 imuc Employment Agreement Termination Notice Period
EmploymentAgreementTerminationNoticePeriod
P90D
CY2013Q1 imuc Operating Lease Monthly Rent
OperatingLeaseMonthlyRent
4410
CY2013Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
13000
CY2012Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
11000
CY2010Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
1654686
CY2010Q1 imuc Stock Issued During Period Shares Private Placement
StockIssuedDuringPeriodSharesPrivatePlacement
1740000
CY2010Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
2716308
CY2010Q2 imuc Stock Issued During Period Shares Private Placement
StockIssuedDuringPeriodSharesPrivatePlacement
2490910
CY2011Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7460129
CY2012Q1 imuc Common Stock Of Public Offering
CommonStockOfPublicOffering
2823670
CY2011Q1 imuc Stock Issued During Period Shares Private Placement
StockIssuedDuringPeriodSharesPrivatePlacement
5219768
CY2011Q1 imuc Common Stock Shares Issuable Private Placement Warrants
CommonStockSharesIssuablePrivatePlacementWarrants
2609898
CY2012Q1 imuc Adjusted Exercise Price Of Warrants
AdjustedExercisePriceOfWarrants
1.87
CY2012Q1 imuc Common Stock Shares Issuable Private Placement Warrants
CommonStockSharesIssuablePrivatePlacementWarrants
4744718
CY2012Q1 imuc Common Stock Warrants Exercise Price Private Placement
CommonStockWarrantsExercisePricePrivatePlacement
1.41
CY2012Q1 imuc Public Offering Expenses
PublicOfferingExpenses
1100000
CY2012Q4 imuc Common Stock Warrants Exercise Price Investor Relations Agreement
CommonStockWarrantsExercisePriceInvestorRelationsAgreement
2.65
CY2012Q4 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
19359553
CY2012Q4 imuc Common Stock Shares Issuable Private Placement Warrants
CommonStockSharesIssuablePrivatePlacementWarrants
4500000
CY2012Q4 imuc Public Offering Expenses
PublicOfferingExpenses
1600000
CY2013Q1 imuc Percentage Of Fair Market Value Of Common Stock
PercentageOfFairMarketValueOfCommonStock
not be less than 100%
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
6000000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
8000000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3584655
CY2013Q1 imuc Percentage Of Common Stock Voting Rights Held
PercentageOfCommonStockVotingRightsHeld
more than 10%
CY2013Q1 imuc Minimum Percentage Of Fair Market Value Of Common Stock
MinimumPercentageOfFairMarketValueOfCommonStock
less than 110%
CY2013Q1 imuc Maximum Exercisable Period Of Options
MaximumExercisablePeriodOfOptions
P10Y
CY2011 imuc Charge To Financing Expense
ChargeToFinancingExpense
397294
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10581194
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
212287
CY2013Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
170401
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
5000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10618080
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
9046978
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.16
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.72
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.02
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.95
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.27
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.06
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y
CY2013Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P3Y4M24D
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15783919
CY2011Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2157408
CY2012Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
368524
CY2012Q1 imuc Warrants Exercised
WarrantsExercised
-575197
CY2013Q1 imuc Warrant Liability Gain Loss Included In Earnings
WarrantLiabilityGainLossIncludedInEarnings
2631683
CY2012Q1 imuc Warrant Liability Gain Loss Included In Earnings
WarrantLiabilityGainLossIncludedInEarnings
4472504
CY2013Q1 imuc Warrants Liability Transfers Net
WarrantsLiabilityTransfersNet
CY2012Q1 imuc Warrants Liability Transfers Net
WarrantsLiabilityTransfersNet
CY2012Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
6423239
CY2013Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2012Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2013Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34
CY2012Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34
CY2013Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.06
CY2012Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.06
CY2013Q1 imuc Change In Fair Value Of Warrant Liability For Income Taxes
ChangeInFairValueOfWarrantLiabilityForIncomeTaxes
0.21
CY2012Q1 imuc Change In Fair Value Of Warrant Liability For Income Taxes
ChangeInFairValueOfWarrantLiabilityForIncomeTaxes
0.2
CY2013Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.19
CY2012Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.2
CY2013Q1 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements
EffectiveIncomeTaxRateReconciliationTaxSettlements
0.0
CY2012Q1 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements
EffectiveIncomeTaxRateReconciliationTaxSettlements
0.0
CY2013Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13692941
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
12821749
CY2013Q1 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
1796954
CY2012Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
1796954
CY2013Q1 us-gaap Valuation Allowance Amount
ValuationAllowanceAmount
15489895
CY2012Q4 us-gaap Valuation Allowance Amount
ValuationAllowanceAmount
14618703
CY2013Q1 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2013Q1 imuc Net Operating Losses Expire Date
NetOperatingLossesExpireDate
expire in 2022 and 2016

Files In Submission

Name View Source Status
0000950123-13-003511-index-headers.html Edgar Link pending
0000950123-13-003511-index.html Edgar Link pending
0000950123-13-003511.txt Edgar Link pending
0000950123-13-003511-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
imuc-10q_20130331.htm Edgar Link pending
imuc-20130331.xml Edgar Link completed
imuc-20130331.xsd Edgar Link pending
imuc-20130331_cal.xml Edgar Link unprocessable
imuc-20130331_def.xml Edgar Link unprocessable
imuc-20130331_lab.xml Edgar Link unprocessable
imuc-20130331_pre.xml Edgar Link unprocessable
imuc-ex10_20130331413.htm Edgar Link pending
imuc-ex31_20130331239.htm Edgar Link pending
imuc-ex31_20130331240.htm Edgar Link pending
imuc-ex32_20130331241.htm Edgar Link pending
imuc-ex32_20130331242.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending